{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:24:35Z","timestamp":1793118275478,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangsu Vcare Pharmatech Co, Ltd"},{"name":"China National Science and Technology Major Project for Key New Drug Development","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00799-9","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:14:12Z","timestamp":1782429252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1\/2 study"],"prefix":"10.1186","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04614740","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shengyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoubing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-6744","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"12","key":"799_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731\u201347. https:\/\/doi.org\/10.1038\/s41571-018-0113-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"799_CR2","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-19-3165","volume":"26","author":"EY Rosen","year":"2020","unstructured":"Rosen EY, Goldman DA, Hechtman JF, et al. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clin Cancer Res. 2020;26(7):1624\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3165.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"799_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","volume":"33","author":"JP Solomon","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38\u201346. https:\/\/doi.org\/10.1038\/s41379-019-0324-7.","journal-title":"Mod Pathol"},{"key":"799_CR4","doi-asserted-by":"publisher","first-page":"175883592097561","DOI":"10.1177\/1758835920975613","volume":"12","author":"A Forsythe","year":"2020","unstructured":"Forsythe A, Zhang W, Phillip Strauss U, Fellous M, Korei M, Keating K. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Ther Adv Med Oncol. 2020;12:1758835920975613. https:\/\/doi.org\/10.1177\/1758835920975613.","journal-title":"Ther Adv Med Oncol"},{"key":"799_CR5","unstructured":"U.S. Food and Drug Administration. VITRAKVI\u00ae (larotrectinib) prescribing information. 2025 Apr. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210861s012lbl.pdf"},{"key":"799_CR6","unstructured":"U.S. Food and Drug Administration. ROZLYTREK\u00ae (entrectinib) prescribing information. 2024 Jan. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212725s011lbl.pdf"},{"issue":"1","key":"799_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","volume":"6","author":"M Russo","year":"2016","unstructured":"Russo M, Misale S, Wei G, et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discov. 2016;6(1):36\u201344. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0940.","journal-title":"Cancer Discov"},{"issue":"8","key":"799_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1714448.","journal-title":"N Engl J Med"},{"issue":"10","key":"799_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","volume":"8","author":"A Drilon","year":"2018","unstructured":"Drilon A, Ou SHI, Cho BC, et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent- Front Mutations. Cancer Discov. 2018;8(10):1227\u201336. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0484.","journal-title":"Cancer Discov"},{"key":"799_CR10","unstructured":"FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors | FDA. Accessed July 9. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-repotrectinib-adult-and-pediatric-patients-ntrk-gene-fusion-positive"},{"issue":"17","key":"799_CR11","doi-asserted-by":"publisher","first-page":"14702","DOI":"10.1021\/acs.jmedchem.4c00361","volume":"67","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Kang J, Lu X. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies. J Med Chem. 2024;67(17):14702\u201322. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00361.","journal-title":"J Med Chem"},{"issue":"2","key":"799_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"11","key":"799_CR13","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963\u201372. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541.","journal-title":"J Clin Oncol"},{"issue":"6","key":"799_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","volume":"12","author":"MJ van den Bent","year":"2011","unstructured":"van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(11)70057-2.","journal-title":"Lancet Oncol"},{"issue":"9","key":"799_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.annonc.2020.05.006","volume":"31","author":"D Liu","year":"2020","unstructured":"Liu D, Flory J, Lin A, et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol. 2020;31(9):1207\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.006.","journal-title":"Ann Oncol"},{"issue":"2","key":"799_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2302299","volume":"390","author":"A Drilon","year":"2024","unstructured":"Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024;390(2):118\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2302299.","journal-title":"N Engl J Med"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00799-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:21:26Z","timestamp":1789950086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00799-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00799-9","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol and all amendments were approved by the Ethics Committee of National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College and conducted in accordance with the principles of the Declaration of Helsinki. All patients understand and sign the written informed consent before enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"97"}}